|
|
Executive Summary: Worldwide Market for Pediatric Drugs, 2nd EditionPublished by: Kalorama Information Executive Summaries Published: Nov. 1, 2005 - 7 Pages Table of ContentsPlease Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report. AbstractKalorma Information's Executive Summaries provide a comprehensive overview of the contents contained in our full-length market intelligence reports.Containing a snapshot of the overall market analysis, each Executive Summary provides a description of the scope and methodology used in the report; a summary of results including market size and market growth; a sampling of charts and graphs when available; and a brief look at the trends shaping the market. The report from which this Executive Summary is compiled is Worldwide Market for Pediatric Drugs, 2nd Edition, and the full study abstract is as follows: Although, the next 15-20 years will shift a majority of the population into the elderly population group, children will continue to remain the bulk of the dependent population worldwide with 9 in every 10 people falling into a pediatric age range in the less developed regions of Africa, Asia and Latin America. Therefore, the treatment of conditions and diseases affecting pediatrics and the healthy growth of children are vital to providing a solid foundation for healthy adults in the future. Addressing the needs of the pediatric population is a challenge of managing human responses within a changing tapestry of anatomic, physiologic, and psychosocial variations. With patients ranging in age from 24 weeks gestation to 18 years and older, optimal health care and patient outcomes can be achieved only through an awareness of the developmental phenomena affecting the responses of infants and children to health problems. Important regulatory factors are also at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. The support of the U.S FDA in mandating pediatric labeling has played an important role in providing the motivation to manufacturers to work with clinicians and researchers in academic settings to study both new and established drugs in children. The result has been and will continue to be an increase in both the quantity and quality of pediatric drugs worldwide.
This completely updated edition of Kalorama’s 2003 study on prescription pediatric drugs focuses on the following treatment segments:
The 500-page report includes global statistical information for conditions and diseases affecting pediatric populations, including detailed discussions and over 180 exhibits. Each segment provides an
In addition, the report includes extensive tables of products in R&D and approved prescription drugs for which additional pediatric information may produce health benefits in the pediatric population. There are also in-depth discussions of current issues and trends affecting the industry and what trends may arise in the future. The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 100 key industry officials, consultants, health care providers, and government personnel were complied to form the primary basis of information-specifically revenue and market share data-presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertain to the world market at the manufacturers’ level. The base year for data was 2004. Historical data are provided for 2002 and 2003 with forecast data provided for 2005 through 2009. Compound annual growth rates (CAGRs) are provided for the 2002-2004, 2004-2009, and 2002-2009 periods for each industry segment covered.
|
|
|||
|
About MarketResearch.com
|
||||